# Which Senolytics Clinical Trials Matter Most in 2026

In 2026, the landscape of senolytics clinical trials has decisively pivoted away from the pursuit of a systemic, whole-body "fountain of youth" toward highly precise, localized interventions for specific age-related diseases. While next-generation drugs are showing remarkable efficacy in early human trials—such as Rubedo Life Sciences achieving a 46% reduction in precancerous skin lesions—high-profile setbacks from pioneers like Unity Biotechnology have introduced a necessary dose of clinical realism. The overriding consensus is that selectively clearing senescent cells can profoundly alter disease trajectories, but only when combined with "hit-and-run" dosing regimens, precise tissue targeting, and early intervention before irreversible structural damage occurs.

## The Evolution of Senotherapeutics: From Theory to Clinical Reality

To understand the stakes of the 2026 clinical pipeline, one must first understand the fundamental biology that these drugs are attempting to manipulate. Over the past decade, the field of geroscience has radically transformed our understanding of how and why we age. In 2013, researchers codified the original "Hallmarks of Aging," a framework that was subsequently expanded in 2023 to include twelve distinct, interconnected processes [cite: 1, 2]. Among these hallmarks—which include genomic instability, mitochondrial dysfunction, and telomere attrition—cellular senescence has emerged as arguably the most actionable target for pharmaceutical intervention [cite: 2, 3].

Cellular senescence is fundamentally a state of permanent growth arrest. When a cell sustains irreparable damage from oxidative stress, radiation, oncogene activation, or simply the natural shortening of its telomeres after repeated division, it faces a biological crossroads [cite: 2, 4]. Ideally, a damaged cell will undergo apoptosis (programmed cell death) or be swiftly cleared by a healthy immune system. However, a fraction of these damaged cells refuse to die [cite: 2, 4]. They enter senescence, a state where they stop dividing but remain metabolically active [cite: 4, 5]. 

In youth, transient cellular senescence is actually beneficial; it acts as a potent anti-cancer mechanism by halting the replication of mutated DNA, and it plays a vital role in wound healing and embryonic development [cite: 4, 5]. But as humans age, the immune system's ability to police and clear these cells deteriorates [cite: 1, 6]. The result is a slow, insidious accumulation of senescent cells across virtually every tissue and organ in the body [cite: 2, 6].

### The Threat of "Zombie Cells" and the SASP

Scientists frequently refer to senescent cells colloquially as "zombie cells" because they are effectively trapped in a twilight state—neither fully functioning nor dead [cite: 4, 7]. If these cells simply sat inertly in our tissues, they would be relatively harmless. Unfortunately, they are highly active, secreting a complex and toxic cocktail of pro-inflammatory cytokines, chemokines, growth factors, and tissue-remodeling proteases [cite: 2, 7]. This phenomenon is known as the Senescence-Associated Secretory Phenotype, or SASP [cite: 1, 3].

The SASP is the primary engine of age-related disease. It creates a localized environment of chronic, low-grade inflammation, often referred to in the literature as "inflammaging" [cite: 1, 2]. Following a common analogy in the field, if human tissue is a neighborhood, a senescent cell is a crumbling, toxic factory [cite: 4, 7]. The SASP acts as a biological pollutant that seeps into the surrounding extracellular matrix, degrading structural proteins like collagen and pushing neighboring, previously healthy cells into senescence [cite: 1, 4]. This cascade effect explains why a relatively small burden of senescent cells—sometimes comprising less than 1% to 15% of a tissue's total cell population—can drive massive organ dysfunction, systemic frailty, and chronic disease [cite: 7].

### The Mechanics of Senolysis and SCAPs

To survive their own toxic internal environment and resist the body's natural apoptosis signals, senescent cells must upregulate highly specific pro-survival networks. These are known as Senescent Cell Anti-Apoptotic Pathways (SCAPs) [cite: 4, 8]. SCAPs act like biological force fields, keeping the zombie cells alive [cite: 4]. The recognized SCAP networks include the BCL-2 protein family (such as BCL-xL and BCL-w), the PI3K/Akt kinase pathway, p53/p21/serpines, dependence receptors, ephrins, and heat-shock protein 90 (HSP90) [cite: 3, 8, 9]. 

Senolytics are small-molecule drugs engineered to temporarily disable these SCAPs. By knocking out the survival networks that senescent cells uniquely rely upon, senolytics strip away the force field, causing the zombie cells to succumb to their own toxic stress and undergo apoptosis [cite: 4, 9]. Because healthy, dividing cells do not heavily rely on these specific SCAPs for daily survival, they are theoretically spared from the drug's effects [cite: 4, 10].

This mechanism dictates the unique dosing strategy required for senolytics. Unlike traditional medications for chronic conditions like hypertension or diabetes, which require continuous daily dosing, senolytics are administered using an intermittent or "hit-and-run" approach [cite: 5, 11]. Because senescent cells take weeks or even months to accumulate, a brief, high-dose exposure to a senolytic agent is sufficient to clear the existing burden. Once the senescent cells are triggered into apoptosis and cleared by the immune system, the patient can remain off the drug for an extended period until the senescent burden slowly rebuilds [cite: 5, 12]. This hit-and-run strategy drastically reduces the potential for off-target toxicity and prevents interference with the acute, beneficial senescence needed for routine wound healing [cite: 5, 12].



## The 2026 Clinical Pipeline: Shifting to Precision Medicine

In the early days of senolytics research, the prevailing hope was that systemic administration of these drugs could yield a generalized "anti-aging" effect, treating everything from osteoarthritis to cardiovascular decline simultaneously. By 2026, the clinical reality is far more nuanced. Research has proven that senescence is highly heterogeneous; a zombie cell in the retina relies on different SCAPs than a zombie cell in liver adipose tissue [cite: 10, 13]. Consequently, the industry has shifted toward precision senotherapy, developing distinct molecules for distinct organ systems [cite: 6, 13].

Table 1 outlines the most critical therapeutic assets actively moving through global clinical trials as of mid-2026.

[image delta #1, 0 bytes]



| Drug / Compound | Developer / Sponsor | Primary Mechanism | Target Indication | Current Clinical Phase | 2026 Status & Key Milestones |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **RLS-1496** | Rubedo Life Sciences | GPX4 Modulator | Actinic Keratosis (AK), Psoriasis | Phase 1b/2a | Met primary endpoints; **46% reduction** in AK lesions. Advancing to Phase 2b dose-ranging study. |
| **Dasatinib + Quercetin (D+Q)** | Mayo Clinic / Wake Forest | Tyrosine Kinase + Flavonoid | Alzheimer's Disease | Phase 2 | Phase 1 (SToMP-AD) confirmed CSF penetrance; Phase 2 (ALSENLITE) ongoing. |
| **Fisetin** | UCLA / Univ. of Minnesota | Natural Flavonoid | Cancer Frailty (TROFFi), Sepsis | Phase 2 | Ongoing trials (STOP-Sepsis, TROFFi) analyzing 6-minute walk distance and organ failure metrics. |
| **HTX-001** | HAYA Therapeutics | Antisense Oligonucleotide (WISPER lncRNA) | Hypertrophic Cardiomyopathy | Phase 1a/b | First cohort dosed in May 2026. Focuses on cellular reprogramming of cardiac fibrosis. |
| **RS5614** | Renascience (Japan) | PAI-1 Inhibitor | Lung & Pancreatic Cancer | Phase 2 | Ongoing in Japan; testing synergistic effects with standard cancer treatments. |
| **UBX1325 (foselutoclax)** | Unity Biotechnology | BCL-xL Inhibitor | Diabetic Macular Edema (DME) | Phase 2b | Missed primary week 20-24 non-inferiority endpoint vs. standard of care. Company restructuring. |

### Dermatology and Skin Aging: The Breakthrough of RLS-1496

One of the most consequential clinical readouts of early 2026 came from Rubedo Life Sciences, an AI-driven biotechnology company that is pioneering a novel category of drugs termed "Adaptive SenoTherapeutics" [cite: 14, 15]. Their lead candidate, RLS-1496, represents a significant evolution in the field as it moves away from repurposed chemotherapies toward purpose-built, highly selective molecules.

In May 2026, Rubedo unveiled highly positive preliminary results from a Phase 1b/2a trial testing RLS-1496 in patients with actinic keratosis (AK) [cite: 14, 16]. Actinic keratosis is an age-related dermatological condition characterized by precancerous skin lesions that are heavily driven by cellular senescence and cumulative UV-induced DNA damage [cite: 15, 16]. If left untreated, these lesions can progress to squamous cell carcinoma.

RLS-1496 is entirely novel; it is the first drug to ever enter human trials designed to selectively modulate glutathione peroxidase 4 (GPX4) [cite: 14, 16]. Research has demonstrated that in specific pathological senescent cells, the aging process is intrinsically linked to a severe imbalance in GPX4 enzymes [cite: 14, 16]. By targeting this exact vulnerability, RLS-1496 forces the precancerous senescent cells into apoptosis while leaving healthy dermal cells unharmed.

**The Trial Data and Implications:**
The open-label, multi-center US trial assessed the safety, tolerability, and clinical effects of a 1% topical cream formulation of RLS-1496 applied to the forearms of adult patients [cite: 14, 16]. At the four-week mark, the data revealed a striking **46% reduction in actinic keratosis lesion counts**, compared to just an 11% reduction in the untreated control group [cite: 14, 15].

The efficacy data is highly encouraging, but the safety profile is what positions RLS-1496 as a potential paradigm shift in dermatology. The current standard of care for actinic keratosis relies on topical chemotherapies or immunomodulators that are notoriously harsh, causing severe local erythema (redness), peeling, blistering, and intense pain [cite: 14]. This side-effect burden results in massive non-compliance, with many elderly patients abandoning treatment weeks before completion [cite: 14]. In stark contrast, the RLS-1496 trial reported that the senolytic cream was exceptionally well-tolerated, causing minimal local irritation [cite: 14, 15]. There were zero serious adverse events (AEs) and no patient discontinuations due to tolerability issues throughout the study [cite: 14, 15].

These US results follow preliminary data from an earlier Phase 1 clinical trial conducted in the European Union, which evaluated RLS-1496 in patients with plaque psoriasis, atopic dermatitis (eczema), and photo-aged skin [cite: 17]. In those cohorts, the drug demonstrated early signs of efficacy, achieving a statistically significant relationship between target engagement and clinical improvement, including an average 20% reduction in epidermal thickness observed via histology over one month [cite: 17, 18]. Furthermore, in atopic dermatitis patients, 25% of subjects on RLS-1496 experienced a highly clinically meaningful reduction in pruritus (itching) [cite: 18, 19].

Armed with this robust Phase 1 and 2a data, Rubedo Life Sciences is scheduled to initiate a larger Phase 2b dose-ranging study for actinic keratosis in the fourth quarter of 2026 [cite: 14].

### Alzheimer's Disease and Neurodegeneration: The D+Q ALSENLITE Trial

While new molecules like RLS-1496 dominate the headlines, the first-generation senolytic combination of Dasatinib and Quercetin (D+Q) remains the most heavily researched intervention in the field [cite: 9, 20]. Dasatinib is an FDA-approved tyrosine kinase inhibitor originally developed for leukemia, while quercetin is a naturally occurring plant flavonoid found in onions and apples [cite: 9, 11]. Discovered as senolytics in 2015, they act synergistically: dasatinib targets SCAPs in senescent preadipocytes and endothelial cells, while quercetin suppresses BCL-2 and PI3K survival networks, allowing the combination to clear a broader range of zombie cells than either agent could alone [cite: 10, 20].

In 2026, the scientific community is closely monitoring the progression of D+Q in the context of neurodegeneration. Alzheimer's disease (AD) is characterized by the accumulation of amyloid-beta plaques and hyperphosphorylated tau tangles, but recent geroscience research suggests that senescent microglia and astrocytes are the primary culprits driving the devastating neuroinflammation associated with the disease [cite: 21, 22]. These senescent glial cells secrete SASP factors that amplify neurotoxicity, impair synaptic plasticity, and compromise the blood-brain barrier [cite: 22, 23].

The ALSENLITE trial (NCT04785300), an open-label pilot study managed by the Mayo Clinic, is evaluating the safety and target engagement of intermittent D+Q administration in symptomatic adults over 55 who have a clinical diagnosis of probable Alzheimer's disease and confirmed tau-PET biomarker positivity [cite: 24, 25]. The trial protocol utilizes a hit-and-run dosing schedule where subjects take the oral combination for two consecutive days every 15 days, repeating for six cycles [cite: 25].

**CNS Penetrance and Biomarker Outcomes:**
Treating the brain requires navigating the blood-brain barrier (BBB), a notoriously difficult obstacle for small molecules. The ALSENLITE trial builds upon crucial data generated by two preceding Phase 1 trials, SToMP-AD and STAMINA, which evaluated 12 weeks of intermittent D+Q in older adults with mild cognitive impairment and early-stage AD [cite: 22, 26]. 

The biomarker data from these Phase 1 cohorts confirmed that the treatment successfully penetrated the central nervous system. Dasatinib was detected in the cerebrospinal fluid (CSF) of 80% of participants [cite: 22, 26]. Interestingly, quercetin was not detected in the CSF, suggesting that the clinical effects in the brain may be driven primarily by dasatinib's kinase inhibition or by quercetin's peripheral systemic effects modulating overall inflammation [cite: 22, 26].

Crucially, the Phase 1 data indicated biological activity. Plasma inflammatory markers—including key SASP factors—decreased following treatment across both cohorts [cite: 22]. In the SToMP trial, the CTRA (Conserved Transcriptional Response to Adversity) gene expression profile decreased in 80% of participants, suggesting a systemic downregulation of immune stress [cite: 22]. In the STAMINA cohort, researchers observed that reductions in plasma TNF-α significantly correlated with improvements in MoCA (Montreal Cognitive Assessment) scores [cite: 22]. 

However, investigators explicitly caution against over-interpreting these cognitive signals. The Phase 1 trials were extremely small—only five participants in SToMP-AD—and were designed to assess safety and pharmacokinetics, not clinical efficacy [cite: 26, 27]. Furthermore, urinary analysis of metabolites and specific markers of tau and amyloid pathology did not show statistically significant changes in the short 12-week timeframe [cite: 27]. As the larger ALSENLITE trial progresses through 2026, the primary goal is to establish a rigorous, standardized biomarker framework to definitively prove whether senescent glial cells are actually being cleared from the human brain before advancing to fully powered, placebo-controlled Phase 3 studies [cite: 23, 27].

### Cancer Survivorship and Sepsis: The Fisetin Trials

While D+Q relies on a repurposed chemotherapy drug, there is immense clinical interest in purely natural senolytics. Fisetin, a flavonoid found in strawberries, apples, and persimmons, has emerged as a frontrunner [cite: 11, 28]. In preclinical models, fisetin demonstrated greater senolytic potency than quercetin, actively reducing the burden of p16-positive senescent cells in adipose and brain tissue, and extending median lifespan by 10% when administered to late-life mice [cite: 29, 30]. 

Because it is relatively safe and has GRAS (Generally Recognized as Safe) status, fisetin has rapidly advanced into human trials without the extensive regulatory hurdles required for novel synthetics [cite: 11]. In 2026, two major Phase II trials are utilizing fisetin to combat the accelerated aging caused by severe acute medical trauma.

**The TROFFi Trial (Chemotherapy-Induced Frailty):**
Chemotherapy is highly effective at killing rapidly dividing cancer cells, but it inflicts massive collateral DNA damage on healthy tissues. This damage forces normal cells into premature senescence, leading to a rapid, systemic build-up of zombie cells [cite: 28, 31]. For many postmenopausal breast cancer survivors, this therapy-induced senescence manifests as severe skeletal muscle decline, chronic fatigue, and long-term physical frailty that persists long after the cancer is cured [cite: 28, 31].

The TROFFi (Treatment of Frailty with Fisetin) trial (NCT05595499) is an ongoing multicenter, randomized, double-blind, placebo-controlled Phase II study testing whether fisetin can reverse this decline [cite: 32, 33]. The trial is enrolling 88 women with stage I-III breast cancer who exhibit functional decline following chemotherapy [cite: 31]. Participants are randomized to receive either a placebo or a high dose of oral fisetin (20 mg/kg/day) for three consecutive days every two weeks [cite: 31, 32]. 

The primary clinical endpoint is the 6-minute walk distance (6MWD), a highly validated metric of physical function and cardiovascular reserve [cite: 32, 34]. To prove the underlying biology, an embedded mechanistic sub-study of 20 patients is utilizing MRI to measure thigh muscle volume and conducting vastus lateralis muscle biopsies to assess mitochondrial respiration, muscle fiber composition, and direct histological markers of senescent cell clearance [cite: 31].

**The STOP-Sepsis Trial:**
In acute critical care settings, the burden of senescent cells can be the difference between life and death. Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection [cite: 35, 36]. Older adults disproportionately suffer from sepsis because their existing burden of senescent immune cells (which resist apoptosis and exhibit altered gene expression) amplifies the inflammatory storm [cite: 37, 38].

The STOP-Sepsis trial (NCT05758246), sponsored by the University of Minnesota, is a multi-center, adaptive allocation Phase 2 clinical trial testing fisetin in 220 elderly patients (age > 65) diagnosed with sepsis [cite: 35, 37]. Patients receive either a single oral bolus dose of fisetin (20 mg/kg), two doses spaced a day apart, or a placebo [cite: 35, 38]. The hypothesis is that intervening early with a rapid senolytic hit will quickly clear senescent CD3+ T-cells, dampen the maladaptive inflammatory signaling, and halt the progression to multiorgan failure [cite: 35, 38]. The primary outcome is a composite score assessing cardiovascular, respiratory, and renal failure at seven days [cite: 35, 38]. With primary completion estimated for August 2026, STOP-Sepsis represents one of the most ambitious attempts to use a senolytic in an acute, critical-care environment [cite: 37].

### Cardiac Fibrosis and RNA Therapeutics: HAYA Therapeutics

As the senolytics field matures, it is expanding beyond small molecules into the realm of precision genetic medicine. In May 2026, Swiss-American biotechnology company HAYA Therapeutics announced the successful dosing of the first cohort in its Phase 1a/b clinical trial for HTX-001 [cite: 39, 40]. 

HTX-001 represents a paradigm shift from traditional senolytics (which kill cells) toward cellular reprogramming [cite: 40, 41]. The investigational therapy is a first-in-class antisense oligonucleotide designed to downregulate WISPER, a heart stress-specific long non-coding RNA (lncRNA) located in the "dark genome" [cite: 39, 42]. 

WISPER, discovered in 2017 by HAYA's CEO Dr. Samir Ounzain, acts as a master regulator of fibrotic signaling pathways in the heart [cite: 39, 41]. In diseases like nonobstructive hypertrophic cardiomyopathy (nHCM)—which accounts for 30% to 60% of all hypertrophic cardiomyopathy cases—cardiac myofibroblasts enter a pathological state, overexpressing WISPER and driving the extensive accumulation of rigid scar tissue (fibrosis) that impairs the heart's ability to relax and pump blood [cite: 39, 43]. 

Current standard-of-care treatments for nHCM only manage symptoms and attempt to improve blood flow; none directly target the underlying fibrotic process [cite: 39, 43]. By delivering an antisense oligonucleotide to suppress WISPER activity directly within the cardiac myofibroblasts, HTX-001 aims to reprogram these disease-driving cells from a pathogenic, senescence-like state back toward a normal, healthy phenotype [cite: 39, 43]. Following preclinical studies that demonstrated reduced pathological fibrosis and improved heart function, the Phase 1 trial is currently assessing safety, tolerability, and pharmacodynamics across multiple ascending-dose cohorts in healthy volunteers before progressing to patients with nHCM [cite: 41, 43].

### Oncology and Global Expansion: The jRCT in Japan

The geographic center of gravity for aging research is naturally shifting toward nations with the oldest populations. Japan has established a robust framework for regenerative and aging-related medicine under the Japan Registry of Clinical Trials (jRCT) [cite: 44, 45]. 

A standout in the Japanese senotherapeutics pipeline is **RS5614**, an oral small-molecule drug developed by the biotech venture Renascience in collaboration with Tohoku University [cite: 46, 47]. RS5614 is a highly specific inhibitor of PAI-1 (plasminogen activator inhibitor-1) [cite: 47]. PAI-1 is a well-documented and critical component of the SASP, deeply involved in maintaining cellular senescence, promoting tissue fibrosis, and facilitating immune evasion [cite: 8, 48].

In May 2026, Renascience hit a critical milestone, initiating Phase II clinical trials for RS5614 as an adjuvant therapy in both non-small cell lung cancer and pancreatic cancer [cite: 47]. The clinical rationale leverages the fact that primary chemotherapy regimens induce massive cellular senescence in the tumor microenvironment [cite: 28, 47]. These therapy-induced senescent cells secrete SASP factors that inadvertently protect the surviving cancer cells and promote resistance to further treatment. By administering the PAI-1 inhibitor RS5614, researchers aim to selectively strip away this senescent cellular shield, substantially boosting the efficacy of standard oncology treatments [cite: 46, 47]. The trial initiation triggered a surge of investor enthusiasm, driving Renascience shares to their daily limit up on the Tokyo Stock Exchange [cite: 47].

## The Cautionary Tale: Unity Biotechnology's Clinical Setbacks

While 2026 has delivered promising data for precision and next-generation senolytics, the field's overarching narrative has been profoundly shaped by the severe clinical stumbles of its earliest pioneer. The trajectory of Unity Biotechnology serves as a vital case study regarding the biological limitations of senescent cell clearance.

Unity Biotechnology was the first highly capitalized company to bring senolytics into human trials. Their strategy was highly targeted: recognizing the dangers of systemic drug delivery, they focused on ophthalmology [cite: 2]. Their lead asset, UBX1325 (foselutoclax), is a potent small-molecule inhibitor of BCL-xL, a member of the BCL-2 family of apoptosis-regulating proteins that retinal senescent cells desperately rely on for survival [cite: 49, 50]. The clinical hypothesis was straightforward: in diseases like Diabetic Macular Edema (DME) and wet Age-related Macular Degeneration (wAMD), senescent cells accumulate in the delicate blood vessels of the retina, driving vascular leakage and vision loss [cite: 49, 51]. Injecting a senolytic directly into the eye should clear these toxic cells and restore vascular integrity [cite: 2, 49].

To secure regulatory approval and market share, UBX1325 was evaluated in the Phase 2b ASPIRE trial against a formidable benchmark: aflibercept (marketed as Eylea), the leading anti-VEGF standard of care that generates billions in annual revenue [cite: 51, 52]. The double-masked study enrolled 52 patients with previously treated, active DME who had experienced suboptimal benefits from prior therapies [cite: 50, 52]. Participants were randomized to receive injections of either 10 μg of UBX1325 or 2 mg of aflibercept every eight weeks for six months [cite: 52].

**The Clinical Failure:**
The trial's primary endpoint was designed to prove statistical non-inferiority to aflibercept based on the average change in Best Corrected Visual Acuity (BCVA) at weeks 20 and 24, measured by the standard ETDRS eye chart letter score [cite: 51, 52]. 

The trial missed this primary endpoint [cite: 51, 52]. Across the 20- to 24-week average, patients in the UBX1325 arm gained only 3.7 letters from their baseline vision, compared to a stronger 5.1-letter gain for patients in the Eylea control arm [cite: 52]. At the specific 20-week mark, UBX1325 was definitively inferior to the standard of care [cite: 52]. 

While Unity executives emphasized that UBX1325 achieved non-inferiority at week 36 (+5.5 letters for UBX1325 vs. +5.3 for Eylea), and that the drug actually outperformed Eylea in a pre-specified subgroup of patients with moderately aggressive disease (central subfield thickness under 400 microns), the damage was done [cite: 50, 51, 52]. In biotechnology, failing a primary endpoint against a dominant standard of care is generally viewed as a commercial failure [cite: 51, 52]. The financial markets reacted ruthlessly, sending Unity's stock plummeting over 33% [cite: 52]. 

By May 2025, Unity's board of directors approved a drastic restructuring plan. The company announced a total reduction in force, laying off its entire operational workforce while transitioning its CEO, CFO, and Chief Legal Officer into consulting roles to manage the closeout of the ASPIRE study [cite: 50, 53]. Throughout 2026, Unity exists effectively as a shell, seeking "strategic alternatives" or an established ophthalmic partner willing to acquire and salvage the UBX1325 program [cite: 50, 53, 54].

**The Scientific Lesson for the Industry:**
The failure of UBX1325 in DME—and the earlier failure of Unity's knee osteoarthritis drug, UBX0101—provides the most important scientific lesson of the decade for the senotherapeutics industry. Clearing senescent cells does not automatically translate into tissue regeneration or clinically meaningful recovery [cite: 13]. If a disease has progressed to the point where the extracellular matrix is destroyed or the neural/vascular architecture is fundamentally compromised, simply killing the zombie cells will not rebuild the eye or the joint [cite: 13]. Going forward into the late 2020s, senolytics must be viewed as early interventions designed to halt the progression of SASP-induced damage, not as magical regenerative cures for end-stage structural decay [cite: 13].

## Senolytics Safety: Clinical Drugs vs. Dietary Supplements

As the clinical results of senolytics have reached the mainstream press, a massive consumer market for "anti-aging" supplements has proliferated. However, scientists draw a strict line between the safety profiles of targeted pharmaceutical inhibitors and over-the-counter natural flavonoids.

### The Risks of Repurposed Pharmaceuticals
First-generation clinical senolytics, particularly the tyrosine kinase inhibitor Dasatinib and BCL-2/BCL-xL inhibitors like Navitoclax (ABT-263), carry substantial physiological risks [cite: 6, 10]. Because they forcefully disrupt fundamental cellular survival pathways that are highly conserved across mammalian biology, they suffer from a narrow therapeutic index [cite: 6, 10]. If misdosed, they can easily trigger off-target apoptosis in healthy, non-senescent cells [cite: 10]. 

For example, Navitoclax frequently induces dose-dependent thrombocytopenia—a dangerous drop in blood platelets—because platelets rely heavily on BCL-xL for survival [cite: 6]. Furthermore, the long-term systemic clearance of all senescent cells via aggressive pharmaceuticals may inadvertently impair the acute senescence required for routine wound repair, tissue remodeling, and tumor suppression [cite: 4, 5]. For these reasons, medical consensus in 2026 strictly dictates that pharmacological senolytic agents should never be used off-label outside of rigorously monitored clinical trials [cite: 55].

### The Nuances of Natural Flavonoids (Quercetin and Fisetin)
Conversely, naturally occurring flavonoids have much broader safety margins, though they are not without complex biological interactions. Table 2 details the comparison between the two leading natural senolytics.

| Characteristic | Quercetin | Fisetin |
| :--- | :--- | :--- |
| **Natural Sources** | Onions, citrus fruits, apples [cite: 11, 56] | Strawberries, persimmons, apples [cite: 11, 28] |
| **Primary Activity** | Broad antioxidant, antihistamine, mild senolytic (when combined with Dasatinib) [cite: 11, 57] | Potent selective senolytic, Nrf2 upregulator [cite: 12, 57] |
| **Established Safety Limits** | Up to 1,000 mg – 2,000 mg/day (short-term, 12 weeks) [cite: 11] | Safe at high "hit-and-run" doses (e.g., 20 mg/kg/day for consecutive days) [cite: 11] |
| **Potential Side Effects & Interactions** | Mild headaches; inhibits CYP450 liver enzymes (can interact with statins/blood thinners); pro-oxidant in presence of transition metals [cite: 55, 57] | Mild gastrointestinal upset at very high doses; long-term continuous safety data still emerging [cite: 11, 57] |

While supplement manufacturers heavily promote the daily consumption of quercetin and fisetin capsules, leading geroscience researchers stress that continuous, daily dosing fundamentally misunderstands how senolytics actually work [cite: 5, 11]. Because zombie cells take a long time to form, a daily regimen provides no additional senescent clearance benefit once the initial burden is removed, and may unnecessarily tax liver metabolism or trigger drug-drug interactions via CYP450 inhibition [cite: 5, 57]. The clinical efficacy of these compounds remains firmly tied to the intermittent "hit-and-run" protocol.

## Bottom line

The senolytics landscape in 2026 has shed the sensationalism of systemic age-reversal in favor of rigorous, precision medicine targeting localized diseases. Breakthroughs like Rubedo's RLS-1496 for precancerous skin lesions and the continued advancement of fisetin for cancer frailty prove that clearing senescent cells can yield profound, disease-modifying clinical benefits. However, the commercial failure of Unity Biotechnology's ophthalmic program serves as a stark reminder that removing "zombie cells" is not enough to regenerate tissue that is already structurally destroyed. Ultimately, the future of senotherapy relies on intervening early in the disease process, optimizing intermittent dosing, and developing precise biomarkers to measure senescent burden before irreversible damage occurs.

***

## Sources
1. [EU Clinical Trials Register](https://www.clinicaltrialsregister.eu/ctr-search/search?query)
2. [Rubedo's RLS-1496 Reduces Actinic Keratosis](https://lasvegassun.com/news/2026/may/28/rubedos-rls-1496-reduces-actinic-keratosis-pre-can/)
3. [EU Clinical Trials Register Home](https://www.clinicaltrialsregister.eu/)
4. [ACT EU Monitoring the European clinical trials environment](https://accelerating-clinical-trials.europa.eu/document/download/b74dc2c9-13cc-4e5d-b2d9-09baf2bfb511_en?filename=ACT%20EU%20Monitoring%20the%20European%20clinical%20trials%20environment%20report%20March%202026.pdf)
5. [Clinical Trials Information System (CTIS)](https://euclinicaltrials.eu/)
6. [Rubedo's RLS-1496 Reduces Actinic Keratosis - AFP](https://www.afp.com/en/infos/rubedos-rls-1496-reduces-actinic-keratosis-pre-cancerous-skin-lesions-46-four-weeks-minimal)
7. [Rubedo Phase 1 Results for Psoriasis and Atopic Dermatitis](https://www.businesswire.com/news/home/20260326810310/en/Rubedo-Life-Sciences-Announces-Positive-Preliminary-Phase-1-Clinical-Trial-Results-for-Lead-Drug-Candidate-RLS-1496-in-Patients-with-Plaque-Psoriasis-Atopic-Dermatitis-and-Skin-Aging)
8. [RLS-1496 Phase 1 early signs of efficacy - MEXC](https://www.mexc.com/news/989519)
9. [Rubedo Phase 1b/2a Actinic Keratosis Results - BioSpace](https://www.biospace.com/press-releases/rubedos-rls-1496-reduces-actinic-keratosis-pre-cancerous-skin-lesions-by-46-at-four-weeks-with-minimal-irritation-in-preliminary-results-of-phase-1b-2a-study)
10. [First Human Data for Rubedo Life Sciences Senolytic Drug](https://www.fightaging.org/archives/2026/04/first-human-data-for-rubedo-life-sciences-senolytic-drug-rls-1496/)
11. [HAYA Therapeutics Advances HTX-001 Into Phase 1](https://patientworthy.com/2026/05/31/haya-therapeutics-advances-first-in-class-rna-therapy-into-phase-1-trial-for-cardiac-fibrosis/)
12. [HAYA Therapeutics starts clinical trial for heart disease therapy](https://www.venturelab.swiss/HAYA-Therapeutics-starts-clinical-trial-for-heart-disease-therapy)
13. [HAYA Phase 1 clinical trial HTX001 - BioAlps](https://bioalps.org/haya-phase1-clinical-trial-htx001/)
14. [HAYA Therapeutics announces first cohort dosed - BioSpace](https://www.biospace.com/press-releases/haya-therapeutics-announces-first-cohort-dosed-in-phase-1-clinical-trial-of-htx-001-an-investigational-precision-cellular-reprogramming-therapy-for-cardiac-fibrosis)
15. [HAYA Therapeutics starts the clinical phase](https://technology-outlook.satw.ch/en/news-1/from-the-vision-to-the-first-patients-haya-therapeutics-starts-the-clinical-phase)
16. [Unity's eye treatment fails to match Eylea](https://www.fiercebiotech.com/biotech/unitys-eye-treatment-fails-match-eylea-though-analysts-still-see-path-forward)
17. [Unity Bio lays off staff and seeks strategic alternatives](https://longevity.technology/news/unity-bio-lays-off-staff-and-seeks-strategic-alternatives/)
18. [Unity Biotechnology Announces Complete 36-Week ASPIRE Results](https://www.biospace.com/press-releases/unity-biotechnology-announces-complete-36-week-results-from-the-aspire-phase-2b-study-of-ubx1325-in-diabetic-macular-edema-and-provides-corporate-updates)
19. [Unity Biotechnology upcoming trial data](https://www.ophthalmologytimes.com/view/unity-biotechnology-announces-upcoming-trial-data-and-new-board-of-directors-member)
20. [Unity Biotechnology ASPIRE Phase 2b Results - GlobeNewswire](https://www.globenewswire.com/news-release/2025/05/05/3074007/0/en/unity-biotechnology-announces-complete-36-week-results-from-the-aspire-phase-2b-study-of-ubx1325-in-diabetic-macular-edema-and-provides-corporate-updates.html)
21. [Japan Registry of Clinical Trials jRCT Disclosure](https://disclosure.global/country/jp)
22. [Bioregistry - Japan Registry of Clinical Trials](https://bioregistry.io/jrct)
23. [Japan Registry of Clinical Trials - BigGo Finance](https://finance.biggo.com/s/Japan%20Registry%20of%20Clinical%20Trials)
24. [Clinical Trial Activity in Japan Trends](https://pharpoint.com/resources/clinical-trial-activity-japan-taiwan-2105-2025-trends/)
25. [TME Therapeutics - Clinical Trials](https://tme-tx.com/clinical-trials/)
26. [Past and Future Directions for Research on Cellular Senescence](https://www.researchgate.net/publication/374101746_Past_and_Future_Directions_for_Research_on_Cellular_Senescence)
27. [Senolytic Therapy Market - Market Intelo](https://marketintelo.com/report/senolytic-therapy-market)
28. [Quercetin in neurotherapeutics - Bio-Integration](https://bio-integration.org/10-15212-bioi-2025-0073/)
29. [Quercetin targets in HD - ScienceOpen](https://www.scienceopen.com/hosted-document?doi=10.15212/bioi-2025-0073)
30. [Preprints - Alzheimer's therapies](https://www.preprints.org/manuscript/202509.1889)
31. [Anti-AD effects of Quercetin - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10472810/)
32. [Google Search: time in Japan](https://www.google.com/search?q=time+in+Japan)
33. [NCT05758246 - STOP-Sepsis Trial](https://clinicaltrials.gov/study/NCT05758246)
34. [What drives Senescence in Trauma, Shock, and Sepsis](https://www.researchgate.net/publication/405297184_Beyond_Survival_What_drives_Senescence_in_Trauma_Shock_and_Sepsis)
35. [Fisetin Senolytic Clinical Trial 2025](https://wellnessradar.ca/articles/fisetin-senolytic-clinical-trial-2025)
36. [Senolytics To slOw Progression of Sepsis (STOP-Sepsis) protocol](https://pmc.ncbi.nlm.nih.gov/articles/PMC11492760/)
37. [STOP-Sepsis in elderly patients Study protocol - ResearchGate](https://www.researchgate.net/publication/385106963_Senolytics_To_slOw_Progression_of_Sepsis_STOP-Sepsis_in_elderly_patients_Study_protocol_for_a_multicenter_randomized_adaptive_allocation_clinical_trial)
38. [Foselutoclax - Wikipedia](https://en.wikipedia.org/wiki/Foselutoclax)
39. [UNITY Biotechnology Phase IIb trial - FirstWord Pharma](https://firstwordpharma.com/story/5944275)
40. [Unity Biotechnology upcoming trial data and board member](https://www.ophthalmologytimes.com/view/unity-biotechnology-announces-upcoming-trial-data-and-new-board-of-directors-member)
41. [Unity Biotechnology Announces Complete 36-Week ASPIRE Results - BioSpace](https://www.biospace.com/press-releases/unity-biotechnology-announces-complete-36-week-results-from-the-aspire-phase-2b-study-of-ubx1325-in-diabetic-macular-edema-and-provides-corporate-updates)
42. [Unity's eye treatment fails to match Eylea - FierceBiotech](https://www.fiercebiotech.com/biotech/unitys-eye-treatment-fails-match-eylea-though-analysts-still-see-path-forward)
43. [ISSCR 2024 Program Guide](https://static1.squarespace.com/static/611faaa8fee682525ee16489/t/684cfee65031197e75903e9b/1749876585401/ISSCR_AM24_ProgramGuide_V4+%281%29.pdf)
44. [Can fisetin reverse frailty in breast cancer survivors?](https://www.youtube.com/watch?v=qw_AVPI56rY)
45. [The TROFFi study rationale and trial design - PubMed](https://pubmed.ncbi.nlm.nih.gov/41835341/)
46. [NCT05595499 - TROFFi Trial](https://clinicaltrials.gov/study/NCT05595499)
47. [Targeting senescence to reverse chemotherapy-induced muscle aging](https://aacrjournals.org/cancerres/article/86/8_Supplement/LB322/783372/Abstract-LB322-Targeting-senescence-to-reverse)
48. [A phase II randomized study of fisetin to improve physical function (TROFFi)](https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS1645)
49. [Google Search: time in Japan](https://www.google.com/search?q=time+in+Japan)
50. [NCT04785300 - ALSENLITE: Senolytics for Alzheimer's Disease](https://clinicaltrials.gov/study/NCT04785300)
51. [Combination Therapy Demonstrates Clear Senescent Cells in Alzheimer's](https://www.neurologylive.com/view/combination-therapy-demonstrates-clear-senescent-cells-alzheimers)
52. [Comparison of Fisetin and D+Q](https://www.rapamycin.news/t/grok-comparison-of-fisetin-and-d-q/23339)
53. [Mayo Clinic Clinical Trials - Dementia](https://www.mayo.edu/research/clinical-trials/diseases-conditions/dementia)
54. [ALSENLITE trial details - WithPower](https://www.withpower.com/trial/phase-2-cognitive-dysfunction-7-2021-dc23a)
55. [Chemprop Machine Learning Package](https://www.researchgate.net/publication/376841053_Chemprop_A_Machine_Learning_Package_for_Chemical_Property_Prediction)
56. [NCT04313634 - Senolytics to Improve Skeletal Health](https://clinicaltrials.gov/study/NCT04313634)
57. [SGLT2 inhibition eliminates senescent cells - EurekAlert](https://www.eurekalert.org/news-releases/1046133)
58. [jRCT - Japan Registry of Clinical Trials](https://jrct.mhlw.go.jp/en-top)
59. [Bioregistry - jRCT](https://bioregistry.io/jrct)
60. [Japan Registry of Clinical Trials - BigGo](https://finance.biggo.com/s/Japan%20Registry%20of%20Clinical%20Trials)
61. [Senolytics mechanism analogy - Bio-Tech Ventures](https://www.bio-tech.ventures/home)
62. [Anti-Aging Master Guide - BellyProof](https://bellyproof.com/science/anti-aging-master-guide/)
63. [Hallmark 10 - Oxford Longevity Project](https://oxfordlongevityproject.org/insights/hallmark-10)
64. [Longevity - Lisa Pedrosa](https://www.lisapedrosa.com/longevity/)
65. [Herbal Medicine - Collective Health Center](https://www.collectivehealthcenter.com/category/herbal-medicine/)
66. [Senolytic Research Timeline - Stacking Years](https://www.stackingyears.com/learn/senolytic-research-timeline)
67. [Reviewing the Development of Novel Senotherapeutics](https://www.fightaging.org/archives/2026/03/reviewing-the-development-of-novel-senotherapeutics/)
68. [Results of a Phase 1 Trial of Senolytics for Alzheimer's](https://lifespan.io/results-of-a-phase-1-trial-of-senolytics-for-alzheimers/)
69. [Personalized Medicine Approach to Senolytics Clinical Trials](https://lifespan.io/personalized-medicine-approach-to-senolytics-clinical-trials/)
70. [Clinical data on fisetin and quercetin safety - MASI](https://masi.eu/blogs/longevity-news/clinical-data-on-fisetin-and-quercetin-safety)
71. [Biomedical Gerontology - Quercetin and Fisetin Safety](https://academic.oup.com/biomedgerontology/article/76/6/1144/6126488)
72. [Is it appropriate to use senolytic agents - Dr. Oracle](https://www.droracle.ai/articles/906051/is-it-appropriate-to-use-senolytic-agents-such-as)
73. [Fisetin vs Quercetin - Life Extension](https://www.lifeextension.com/wellness/antioxidants/fisetin-vs-quercetin)
74. [Fisetin vs Quercetin - Ubie Health](https://ubiehealth.com/doctors-note/doctor-fisetin-vs-quercetin-difference-lab-aging-751q4)
75. [The Senolytics Pipeline in 2026 - Longevity Next](https://longevitynext.com/the-senolytics-pipeline-in-2026-where-the-science-still-looks-strong-and-where-it-doesnt/)
76. [Senolytic Therapy Cellular Aging - Active Arabia](https://activearabia.fit/en/senolytic-therapy-cellular-aging-en/)
77. [Targeting Cellular Senescence Kidney Disease - Omnicuris](https://www.omnicuris.com/medshots/daily_updates/targeting-cellular-senescence-kidney-disease)
78. [Endocrine Reviews - Senescent cell accumulation](https://academic.oup.com/edrv/article/45/5/655/7631421)
79. [Senolytics for Alzheimer's disease - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12761975/)
80. [Repurposed senolytic compounds - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC8521777/)
81. [Senolytics and Senomorphics - MDPI](https://www.mdpi.com/1422-0067/21/21/7984)
82. [Repurposing Drugs for Senolytic Effects - ResearchGate](https://www.researchgate.net/publication/349005603_National_Institute_on_Aging_Workshop_Repurposing_Drugs_or_Dietary_Supplements_for_Their_Senolytic_or_Senomorphic_Effects_Considerations_for_Clinical_Trials)
83. [Senolytics and screening approaches - PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10577556/)
84. [Discovery of Multi-Target Senolytics - bioRxiv](https://www.biorxiv.org/content/10.1101/2024.07.09.602796v1)
85. [Cellular Senescence and Senolytics - WALC 2026](https://worldagingconference.com/program/scientific-sessions/cellular-senescence-and-senolytics)
86. [EU Clinical Trials Register](https://www.clinicaltrialsregister.eu/)
87. [Senescence2030 EU](https://senescence2030.eu/)
88. [Consolidated Advice on Clinical Trials - ACT EU](https://accelerating-clinical-trials.europa.eu/our-work/consolidated-advice-clinical-trials_en)
89. [Aging Research at the 2026 Biotech Showcase](https://www.the-scientist.com/aging-research-takes-the-spotlight-at-the-2026-biotech-showcase-73946)
90. [RS5614 Cancer Drug - BigGo Finance](https://finance.biggo.com/s/cancer%20drug)
91. [RS5614 Senolytic Drug - BigGo Finance](https://finance.biggo.com/news/Y3LsRZwBx495nWHnaCHU)
92. [RenaScience RS5614 Trials - BigGo Finance](https://finance.biggo.com/s/RenaScience)
93. [Google Search: time in Japan](https://www.google.com/search?q=time+in+Japan)
94. [Unity Biotechnology upcoming trial data](https://www.ophthalmologytimes.com/view/unity-biotechnology-announces-upcoming-trial-data-and-new-board-of-directors-member)
95. [Unity's eye treatment fails to match Eylea](https://www.fiercebiotech.com/biotech/unitys-eye-treatment-fails-match-eylea-though-analysts-still-see-path-forward)
96. [Unity shares halved as lead asset fails to match Eylea - BioSpace](https://www.biospace.com/unity-shares-nearly-halved-as-lead-asset-fails-to-match-regeneron-s-eylea)
97. [Topline results from phase 2b clinical trial of UBX1325 - Modern Retina](https://www.modernretina.com/view/topline-results-from-phase-2b-clinical-trial-of-ubx1325-for-dme-expected-in-q1-2025)
98. [Unity Bio to Cut Workforce, Seek Strategic Alternatives - Market Scope](https://www.market-scope.com/pages/news/8367/unity-bio-to-cut-workforce-seek-strategic-alternatives-for-ubx1325-in-retina)

**Sources:**
1. [oxfordlongevityproject.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG2EnosS1h6rmH385pbG57uxKydM10aJTV-LBgnq4-WGtAvas0Y6R1n8syE9iPO2g7XS97yprM4pK2DI9upjZf8HoqycCdknV8dv3SchiP8mtneeg5DH-MXSJs5mlN-hQEE643uUookjGSS_icr)
2. [lisapedrosa.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQETR0D8oycePC4yU6AW5Hl1qLC5JpTTlTyyRJ5fSfRGuLUkxb0GI-i0QHKwGoWQKlWD3v2QjXnarrn5uD-pVGJs2C041SklsdqLiAgQgs6o_qNa3zIRukya2QKW8A==)
3. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFEsYlYyR5Tv33Jkmjq8wDvWVM57mAmU5o8X3_DTlQCb0w5dom_F9EX3LB_EWU9tWoqxsb3NcRda9XqxWF_dFfmiVO5Ot-kYmgkSQrm6wsKWaSO6orqJ80MjQ3axyL4kSRgLDcKgTaASXWRumjsHkZRRCutzxMeQdKXhTYMhAsFPI-_2Ot-66hg_ZBAkeZ1mhxGurEexFtkcq9sr63A24s9xEZm4iOArqGiJq0_LNICDtwL6wx0_GiBEDRUbzGyGOL_3qhcRlKrcqJjiy1Zr14p3OlSIlDRuX53ozXZ2j42gkLPLFf_UOAP-c2UJYU_NmrjSWL1ZDCfw13vrWcjmcQUVbGhhlU=)
4. [bio-tech.ventures](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFVwUtreIKhresp4KD1Lt0rC3bwf826T9QCP7T1LeDRAAuUNF10IOPQE-kMa68w7RBAqHUuMEgMCwIN7wKeVeOagR8boUSg2rk1xxIoZipLdC1sp6O6vakh)
5. [collectivehealthcenter.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEgh3BG-z-22cjOwpmHi3h9bWEhAoBEqe5GRH6--_NUads6EEHB0T-duRROuHTANF-akPcwdthC6Opar2LCWCgUIWyUfZ7jQXczpVQCJPXmKdM7oHKOC1Ui_F91KmZy9uIVl_X_irLEVL-ye_QkoLMUhlDvEA8c)
6. [fightaging.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH_DH_dtzqkVa971FxNBTqJt39HpZs7B0E46KcaDzxCIYQQQrq3AN16YsM1ljJhzJUeXp_jkgdo_3Ayrdw1Cfrhg5pPUw9yG2rCKjxlhVedWdLNIIbxEVfVwyKLQnr9W2LwNCYURIFRj6igHTc2kox2-nCMtLLFUbOZC2CrQ4fkPinP_iYb1rTWuq1tpdw6a7CKwoPN1KY=)
7. [bellyproof.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE293LrFarmFtp97o6gPBdDFODunRS3TZdSUbLuWTPgYNf5f3qec74UsXEhrDtg5mK-y96kAyL1jFCr9FQqgOdQVgqI8z_EeTPxva2H4QR22C4wTyeXLW-yLUMbb-QlhHvXtptcwR4PAYX0Xv1T)
8. [biorxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGhPPYsSrarWoC8QIHlZGx2oCQDo-_adtZNM4eK6ewj8mOZt3QdpHHT3BPPdkXYkr_rCf1aZHnIpBZrSiY6GlBk1AsilJi0IpMPfDohSWLMmVOfQA8kd8E0NZXvS8GjLlAoYYlZ3Z4mtyW7T_WwG1XEJw==)
9. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZcwErWDr3mjpy4tXe7MZsNNLXzc-HL6IKSC_n8v46GsqY1Jpv2BQmfZo21TPwPeMed_IDEZ4Nb7LZvlBoxZ0YMe_MW1ovqKaVuCnU24Ey1xYeHgKj44kfsZ3dwblkWA==)
10. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFvY6qLW4M4qzJ4sJJsXToHR5dNSbRWwF3BSNoJKzH0QyDlk9LQOW8XKStuyQ_W8IpTj7TyWKbPxlg4NzMi-PzJFUDohahphADwuCvwV7c5ALh6SD65C1oRIoC_xkk0C0dCEIzbJBWD)
11. [masi.eu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-nhHBRveo_PWxeFfegTEirJa9E67qJCPm9FrffQegDo0WXYCK9vcMSw6_TvQJVRMF2-6xhV92o8Q42k7OBx22_wM-lLHrhrL4-Q115eJQJNeu5O4MhuFOhN0LvNXfp9mK2pgB9-XQnZp0AhkW6nAD4Ase3_bUXt4Q1ghhGp9si8Lq9gIsSNq3)
12. [oup.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHp5-o526Zihz2-_srtAVUqzCK7F214Y5Ikftwqeb2O6ZvOVU-xShYTVcOzHballay5Ec70hcnFBSSMdmdT5qvpDgOs7CgcHEIDZbmLNn1DrjBtufKZJw-GZQG4Q4dZ9jvU93QxL4Er4tsJiz1TP-q9UJ-RB3tUJbn6OA==)
13. [longevitynext.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF82GnNfnYmtvWmd-NhPzZwnoN2_mw_QNL7Cv_Myj-02kOUrpKDBtHdPcgMWYHgemW7u3i6JeJQ73WBeHj-U-Q4-LJgHN379XHah6OsDFI9Jk5SuQW98PLMK_IDCNrQoFGj_TBxxSzLGci4-FU8K1NVRCtEuWFBIsnhAWLEfGkIq1ifT2jRqH4kXdGWTiWTvjHQ0dRYYaD85CuPXxKBEni9RYMXd5CXb1d8)
14. [afp.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFf3tvbdsOlsMRV133xIVPU04AWn7YA8pbPF2ezoI4Lo_xucQg9ea9u2HC_fVdCzxtlm5mSAfhpSEqe6N0JlMFBlAAB0IKp0JJJW2kXwTxBcGWPcVREGI-LIIsqKrJfLfWdS6FGwZR6tTRQw4_3GZCIkQILfP0jV6GzoT20_jKeBoORGpBWq5eoE84VnLkY0vXGPVar3wTLVxePOayOuyD5_pqZ2vCIz8BcGL7hLlg=)
15. [biospace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEIOQ3iKmeKtFxUmLs-MSn5cV2QQW5qaYC8qf3a3yDG9fiwZfWdMTffdFAYAGrQJlsoH8uOdizkLz7hObRwaxPqZFKeAr_xyxLWC3vkkS4-25nsKBhgDLES3E654NkVCrwaZy8oYEUlkSxB2qTQ93xlhR9JvuQcq43z1fAp2qjac__mxQpbx9c77ehMxYeV424J_pjKeRZwguap30FEw0OZ2GKaT3DlIhPYUrTHozfWCOj1sS5z1FeHAOvDtOxsoVPrEcEaz2sDH6zGroqa0XUxZDKprIQiikQJgFGyo9ybUgvsRlC5IbfhzK7gJnBABx8pjF1W568AHhyaI2M=)
16. [lasvegassun.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGEPHXpJEHedV9OP7rgWNr9Ap3cTDSJTPWusQXpI_zcK1K-WIdXTHmFPpZYihxTMpCGpqP9XgOSKs0qMEAJk8fMYLiPd5ERLM3hQgNqRLAXahIZAMQGZ9IAq6pFztaDmgvgPHsobdIZGXDwuC4z-sAksxGktUXZ0oArXdpKjYmYXoXV7W9VbJbj9Kk9wHruXHBDDw==)
17. [businesswire.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEBcCwGsbLOIeY0Cp_UpXFyRaEYcI3t5muQNLzTJZ0b8iEHfKTCuNT06bGSccvf07ATBsZ2WH_dsdRNgE640OhtOKn92S4yCS-4Qrdoj-k7nGHphffnNJ4PzDROdRFLqu2wWdKz1xTGKVfvdnPDCLTKMskZX8Lnju5c4tvbMfo8yNxzq42KgcF4FA7X1z4DlQSlf27lruzwYVeg1ULW_SQRg2RIrwsx2AEd_UuOeSz2EkNYh1F4HL9rpTuZ0lldFDW_VepRIDJzRAac_as20DurBnuakOuit80jlG30xqq2XW7JPoJ2MjmldQ9_NOk741pWJQifC0LZQwy2OqJYFk-9KwaWVKB1yWVogw7JJwzXubK4btU-hh1WTgy4iVblqGtPknHVdOk=)
18. [fightaging.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGina7838iu2Q9wQZUmr_veZ84HZR7Mp2yH59Rs4fQ7sg3qIsFMFaCNealrzrAurlvdPy2vZDckATBJfOHSlz9FZWXUEZ2_GzbnhRKBRzmuWsEcp-RgckjI-71RpTqgL3cK_hHyvBCzSHx7rGBohJ5EB6za-0YUMuC9i3kL9ZfdAaUT7PpKTW37gTw8j7Bs8L6EFZUZm_nl0iaK8E_rgdQuvh230A==)
19. [mexc.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEG5F12OXLKt1c_RXu8cgALzsDAkwk5-sVzQT9Qx6z4xvTf05Zuyo0x-d4J0KYXFvcwSKLSpbL0vnnylaNo9RRNtp18xau0Bv27LMYu1UrMdGKaovwHuA==)
20. [marketintelo.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHZp4bPqui6RGmtmhvDtjg48iHCZpBIs2eYeNP23CEOSgP2tAWTNLhTTp26i5e3nskbDxldA2m9Lo53qWag29r1TiyryBdfMuAh0MRcrvp2gWnGqe7q7qwAD6LlexbQxGdnJmG_5lORixfQGTlUDA==)
21. [bio-integration.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGmfakbotQQkLmmZBkml0eDKyhEdxWnolRB6wChV56lTTPKxO-ubafq3JmFPAI2Mu5VAGgpaHZVp6hCWhn7oqKimICLMUBSmlFvUxmXp1hJMt7VeNxXSu15r_gz1mHHuTIf00W6U8CvuRY2)
22. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH-kKmGcmFfa481gD15jm3aRsPMV9XZ6R8FGcSRpXsH3bD7nxHIt2nyigzjmKxBmndnyVZJbpjmFFYcKbAfjfGYbVDtU6tIjcqG1BhfY60gDAB0fIUKz_43gXUuc-Z4qRt3OoQtv02FNw==)
23. [preprints.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH4OTWwzmGM0dkVZ3lcp7bPCNQb3pcf_hRazXpWeoZ4eYdwTcXyEY1azVgJnuESnDCFTWjXpxRnFhz7GbaBxGaoJ8UElo2MKDIlwiZpu9I9Is7wUmEWA01pk1kyT-4s-56mEWD5reQ=)
24. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE2PoICxzBHkNx-ndO8QDA5nVy1UA0mzqwVimiv7aebY4HZ_aOjqTUzmMumy8TU7KhbEoL-yn7I6BKD-FrWIYzi5XqOOhfFuuYd6XfhSYeflK8lTRhyUVrkhK0EVPNqsur1XjT0v0kRB6194LUv0_FZZEsN04YHE0hR3ci4ZHS0KiDmpR9e7UFs1LWAP9acwQVWHO50nXFAaW3m66nHKLb6TPNk8I2ipQ==)
25. [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEU8lbV5OJfxP9tDGMQ0BO_9gbR6e75FQ4ZIxSt7SwojQXAwtOWMHbmtpzj98iKincxhSvfSDWWComC2MHzqtRyOQcCEJ1c2Im3nRd5Gyl1PYNYRWgjRHsxF2ztLdlU65IGCw==)
26. [neurologylive.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHGDpAiyZL-xN38b9mtybEJtC1aW1gxuJMnjXTeM9Dz-GLuKuyHULiF9eYh6kzBouImhmFZOPWONjHobpamPEPHN1ulwVpzC1BTZVlxZxYFGihXFN8KwcQ1dK3DkMlyGXM5Qv1APDYtDEGGM5TUBOfVkkDijjZnJOa5-RfLumdkMQ3FpccOUD6pnn1vj86deglm3qdSkjgloCgA)
27. [lifespan.io](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG-Y6SPnKJSjonJZoZOxN8IEmJJhvbdunBNomwKhjEv5iTj7HRIFNF6lBbNj1iWAwOJGGTF5I5-Go-TnZ8CLKD2CsXIXeJQmyAEj-toFT5niICblFBhnXZuIwu3Np6QxMlKSEuHshtmVoCe13KV6SpDxS_7iBUSWZFWf--CpVbgvQ1f)
28. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEVVJ6YuNqmYYjbL8SeGZDU7rjQBHq1T18lbxzba0PI8AaAox-xjkZs0tiJ8pmtefwXZn-2epySvrfMHanAIWQ09qMO0DV5tPI4nSUb5sSc0CHSoLogwgWdmguBRAt-kg==)
29. [rapamycin.news](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH1C7L6_dnmo4u-QozTR5412kuwYUZ42RzYikXKNqk2CfVNUkAcr8YRSlMEYT6RrAl59JIjp1ea9Yo0Tu5UnT9BUbUU7UAQlssfAwQEUiS-buQf-II5WxxwYgGXOgafa9HEGhDB_j1u5cW3mSAANc5xtnR9dMmArsG-1E8=)
30. [stackingyears.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGJaAUqOdfu-N53fR30JYZezSy_xq5fB7lnB6PKU9ZvLdH83GrugZDyQXWJGFeG52s6_AehF2Bjj-eLO9hx1hki43eXdcPY2Bkq53zOpQ6leplrd7BJ_3SsHyPYVa6wFZmLVx7fQFmiimIEVlXAdA6Vn6P0DL4=)
31. [aacrjournals.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGdfxOBv9om24X76eHT57CISeBqQCc08AXCdlpU7EgTEL3_y65RiIzoDrgkofH_hZ2ZoUmUw7dqyMsWqZq-MJ86wjQS6h1-HHtlIMG5yrsSSunL1EiFiMzSUqMM0f8FPfRLwqtFtjnZhz6j8NhqJsjez8qBeWL-o9jDn0FniY96mE5m_nauZOXyTWJ4HQH6qmEJz_9OqiwHUwvTJ69UsyPFtByOlV3Hcprjgyy3)
32. [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEr_uq3fRwdbvK9Dq5F1dBIeIUhrtBsiLtmd2UIOG0a467OMVjAbn-eJsrw2k6cSIgC4MjypjvL9_-GTb1xluCayWenNbEeOM6H5e_3Wp8LAaHl1PAGJ8_Cdn8fN_uyurfnRw==)
33. [ascopubs.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGRESwgTlql8W1A_AOqiNdm-zwOpkztEBGjlVJEnBYB_MjX9MwMYiCFdBY9RE58Mx7muiYLY6ZDmeiWutS1OjWeF3P8tr8E6syishF2Alowc0pRTaQg6kVCRhWicxiGHdemHjIEq5IRgKofEd-yYzfrYJzJ)
34. [youtube.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFVaSlZ0uAg1o2lLDt2RiU2U8VmyRUQET6VzOoQLOiiYPylEWiWyneNRoto7rJTpqhB4TusPzGAvhGKIRaxtENfhJ9ecLvKUPL7ulTU8MGdMxeOILCyiLl4DTkuIhO9OEAf)
35. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFwIpmdv8aAzEWp6C5quQBsNeoZFaLo43QjHEFdOk97B2ZH446LEiufrCyWdMsy63XL1Z8G5XTrA0aDtCBFuXcNeak318bTdiDab7DdVX10ENIl05pW_CqmWry-ab48UoBGRlTAj6wO-zJi4T-epKgSMuafIAV6RPkLSlvfb3MnPKfsYFC98gsxjuFKW9NX_ThAhv8T9QxIX2aOKdsLY7iS3mcETb_0DtJ6wA==)
36. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFq2KWzeTQEu579WVvNMUiHjHIF7onrgW9wTlabsj1gnUtKIY-HybQTE3ix1VDWkPodDNIN_zdJwhECvlvaWJGpRYTtlYGbk4kKPmaA7iV6e5cx09tga3v4wpsLxZ9y4WpazlsGpPArgGTnn6Y8rZlNkFFt_lIzSW77SK825v9uw-4jFDpDkqwhBL56nQSANtB9g7Cl1hjzhRAYyH_JwkSNMTaJwfpEeoPZWSoUe1mYKoxHBU9J4_58mDURvVb_4gjTdIuz1CstQh2waPYF6eKzG5HTAjjJkL4i72th-VtDfoQB_YLZzEkerJlUCgOE5OucdNC75dH9a8JGIbsVEaSiqQ==)
37. [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGnLB5VQ_LPhzqpoey8jhyCHCpE2dgEpz7nV5PDttkzmRmG3RB69D2GDeNesiyeYZ-MwrlkEWqSV_WCG1tryb6MuTe1jRtvInyxuZAZZV5s6OK-HEZral6HRMgvCDFcoTD7tQ==)
38. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHYWXQBrgiW3EdBPto8z-KU-sUYgeKAKyDuiv_rPuggO-XizLxzeuCq_xkiDjDhMsy80y8ItSxF7kvjCT_iKjK8DMw6GtV1a8Wo3Icp65e5qsAvsYIsRUo04CSyVyFS3cC4TtqpucF8Gw==)
39. [patientworthy.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEn3tkdbUFxevRE20pHz8_n24mZr6DwMapt65yW7XpJcjWKm74JNiX9L5xKwhtA68BRUbdJtbAuIbJQHExBSA0xBq36FG3GT7L4BDiMkAHlm8yEPskOX7IBYJpZQRDD1YrdvUHqLJDuLn1ubSBe6cFv3v-HzwknIy5FpmfKgBMAQRp9O1Ac5_Y3mijugAEVev7A_VTYlOoRdhCGaryNbj22y-fZHJezfgoyba6UWM-TeBtlO2PVM3tmE5s=)
40. [biospace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE1jzppIa377xFh61mhigz7e_dJ8F9GPNAqx8NvltZdt5gimIVbY8AcARVx5Rl8c7YlElQJS4L87qgy59fWSXBNGIsDLp4uQdcigEpXLOssxGamShqHkldgBEQPquxlOHi41VRtis-WDZkvv_6s-FKY-yl93Pn20IBMFoZoL9GxSGmrI4XE0NcD3bo5inLrbn5z3bx-ozhWhbQRjGF4hp94An9w1GCNDVXRlMp40bhv-BLV5GEzDiwt-5lVqsAppzbYljn0vzqK2xwMgiX-k-uou6UFW8xxKppE8TKdQ6ABCmuLYswEMVf8rlJcHVqEViVAG_IuUbw5EjqF2P4EzHR3hKOH)
41. [bioalps.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHTpig02y1-ywuPr35VX3NEiLZP_vdxL2ZGLQWYU7zAhZIURBBqzAt5FSZf3u2Gs9Lyke9jK5YKOE646rXWgUvW9lAV6SCMfX0vl6bIaG3IYPXiFWfbnIK84ioMIIPCA4-w5H76_XljT_Vahwk=)
42. [satw.ch](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF5_mYBq5dKlUBYbcZk2SJQAJXWuKlepUBrDLwcReuPXYCeaDpX6odYSevNEIh7OwYWe0dTm5EBuYbJTbpf8EzgrZxexbNxVEvG4kyVLNuxgMzMJsU_xUY6Q8qbAzrSDHQ9yKkZ3yTX8xlmhPIwuDEGGQvjJ4JXW8UR0jI4sYdDZ4SXSlmqSHnZR4qiv6A3LSE51lbXF1vn5vmHWB6N_045PzkoODyyUioAWy7HXNWUIyclKxs=)
43. [venturelab.swiss](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGL9OVU0r-iTBJiJyTxsmr_yjNcTwrekemdRy4OpYjkeK7uNO3e4q-crYG9CIY7CP9ok2fFFuAmt1Dj-5j7BuotT_c3xawvj5ydmwAmyIbNPEWgvSmgDFnu0U-lWY8fz3OGmpIJBERuA-kvPeh-ovQyTCN58Y_GQOAqtiRgB3TUiGHgUf0U8HJNpas5Ef4qYBnb0dtB)
44. [disclosure.global](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHMvWHDJ4cY96ZqUVS8vq-4jjb3FB8QPqRNRQVr0_5bkIsATqi0IopflQQZluYe0KJzB-jrHO9Zft8btwgDbH6PaSPri8puZUffxiCTIowaSZ5rVLv5CxND5i8=)
45. [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGDeuevRdN3dAPFF3O8FlxjgTURBbjJ2WgeNTcajl2gP-lwVbtT5Fu-6fDgDq8Tv1dFP5zbQb8snrs29I3YU27te7MoiPX0L_iGQzgVMYqHCWV5FaQKQbbkJPkFjyoA1I4tcw==)
46. [biggo.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHwawJv4kPQskSD4Nu1QS07VwJRnGWfWFUn0HbTbw9ddR48jMNDNfY0lhRfKBLC18Ow886sME1apnHkEurwYSkALCUWollL2G63b0ZZSaNlZn1BVtA2dSmxrNNrf8OisA==)
47. [biggo.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELXlQMAngwIya1mdwiykF7ze3DlSXbylCw9_a5YWQDu4uKSXv-tzH11udfG051jzySLyeR7n-kJNDhAhTHLKB1JleiC6Pw9vvaiS5PketUvg5txUDEQIzvezQ-gYo=)
48. [oup.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE9LRjJmyK-_QFlW1el1zgX1NA98DcSod-ihn7W04g1eR0pLqSXW7PqlAYhFSVw_pXQyDMa3x7NAkU5cOlRtHKLDjMriaUzeE6fong05YWWNPtZ4KvzDa7jfMDfvK3GALzXRWMzn7A6c77Qkgg=)
49. [wikipedia.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEA8dYDYjKfFm61argbKuavLJ4U5MP3OnerxkzOSFw7VN42dWk0JZDa0mg05qzWG1pf5SYz2V7WKOc7jdija6OqdEql1oPEI1fIFj0iDcnswHeAlwOcd19FctQayUqNExM=)
50. [biospace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE-qs6rCIevBTF7pEzw7ocaYsu23mGlkzCRToWpDqfAEdwh8hxmq7uJIqpcqL4hlKwDj4LFj5j8xgR7d-YfM0DcHHXuBRSqGEb0acTEiJfY9RRhpG842oEeDcxQK_O6ZMyH5hiINkeIAfNmfCGENEHREzGvUebCJExi4B8MWwmpqrypgDZb2m2exR7YqR9Im4xfjYBmZlfRZoHYLvCqdfhSDQ7412a2r5TqsLEH3JoNd24b5qtrYDlZ_6S32fXeL5tdI4D_A_aXN6WV4iczfNjUoA-O582Rd1HjvSAyTSxxaBB9q0jpLV7zMGCAouSHby9IifX_QUPoXQ==)
51. [firstwordpharma.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEB4ubomoSajAqjVyghzI4Sc9Vtmi_l7v9Ob8D7Cqxs2WUJc_iqd3SO4N2PsPqGgOf6m8fM3KIsOFSvH_qU6ZVc_-8pd974Wux3leZI1bkH9pvZVmZMvVUV1SGzHHSh6w==)
52. [fiercebiotech.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH_Uc4wl8n6fNuz1-dzUW8D7ImFmeUiZcmveUYoP00qhq75KCdm2uEcFHdA5IV0boLFziXWak7g5lCHE5JK0fM3f3VqLMNt_rbkvsM8F3SY2_wWNDZDhMMYm5kiI7kpwhMzoEArkDAvnZOSMuc8i3qetjm-SQN_yTRgCfDXm545riKsrlDaPFdX6UEkSYIO7ji9OV8AmVfhxSeLY-8d3C4o7K0Qlea-3o1j)
53. [longevity.technology](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGX3TpPHRytBBVO-Ey2tz-NhoASqi7bCTY6ZUY8AoZx8GNEusypVy0p10s_OT5LsYCAAp5ltvTTd-h1AuCNW7iyv7_tDnoYsv50Pz-K7lDSBMRdt3UDVSonJQZu1kXLf8tp5I44qWuugUEb1sgyQjeboSDMoXWFrXvmBo-sdbGBXdGeRhqZKZiVm1iVu_uHQmn-NQ==)
54. [market-scope.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFNZzmzJEyl8aJy4dTKHXuvp3sy-S3Y2c5mZ_H224LMw3To2nIhr4xKLjIonGMMBQ0V-CDX7ic8GPBsNFkQiLSvEqJxXWkDKH81l2yRSzf2SdSQZ0HLW3scw68jGklGgm2nhzpgytekgFKGQj1Mm-NDaePmSANx23rI7GjVNxbvsyLrNZDcvG5cA8baUVon1PNecuumZp9rwXzcX7fwV70KEa7r86_CLWnkyLGcAZfd)
55. [droracle.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8pErxeGDGK2qkI_fUQqG8LdVQWW0LhmDCufxhalaEFCB-Z467AoDCR_CpSmpDPsm08AIX2NSbw1WXSIaOIpNned0vLbkLnbsrxT1VmXaTx5Mlk6o1xB0cVbEmn_zfIk95RtOLb9tX5etmZ9yJaFQ0fq296f0A3pueay4A_rXhW4jpX41_fkqqA2ur8QNkSg==)
56. [lifeextension.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOJlFV9LkWWp0_mEIM0_51NR0lpFLwHTZbvl7myeILtkcUS4wPZNPPBGjxbJvgks2D6oDZ1Cb0MMV_ANShLddI_b9jov2TqnFtccKgZck1iKzrEln9zFVhHOhO6xDmfvE6UAIOHlnNJ141ooDw5BTHSuvSPnESKzxx9qFpWr8=)
57. [ubiehealth.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEEBJzh6O4blF7usbh-GkjBFzZhzjct-1JSzP_I6l0PVXN3Ux0HpRNynxvwxQInqQDRyQWNa3jbA9xslqysJokMSTNx0CBsas5p-VgcMKky7xPqO5QmPSY2jhwVRNv5EoAnsmo69osnLBqRgaS9Atul5qpqSWICc4rh1TAW9sGGaUsTDq1UnFw94LGQ6K9sprM=)